Published in Cell on September 25, 1987
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J (1989) 7.69
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Factors involved in specific transcription by mammalian RNA polymerase II: purification, genetic specificity, and TATA box-promoter interactions of TFIID. Mol Cell Biol (1988) 5.60
NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J (1989) 3.58
A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol (1993) 3.38
Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol Cell Biol (1988) 3.07
Two regions of the adenovirus early region 1A proteins are required for transformation. J Virol (1988) 3.02
A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol (1989) 3.00
Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J Cell Biol (1995) 2.93
Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J (1993) 2.83
The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J (1990) 2.80
Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol (1990) 2.40
Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci U S A (1990) 2.27
Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol (1992) 2.24
Adenovirus E1a prevents the retinoblastoma gene product from repressing the activity of a cellular transcription factor. EMBO J (1992) 2.11
Simian virus 40 large-T antigen expresses a biological activity complementary to the p300-associated transforming function of the adenovirus E1A gene products. Mol Cell Biol (1991) 1.85
The 289-amino acid E1A protein of adenovirus binds zinc in a region that is important for trans-activation. Proc Natl Acad Sci U S A (1988) 1.84
The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J (1996) 1.75
Transcriptional repression by the Rb-related protein p107. Mol Biol Cell (1993) 1.72
Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins. EMBO J (1996) 1.70
Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci U S A (1991) 1.70
Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Res (1991) 1.66
Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family. Mol Cell Biol (1990) 1.66
Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol (2001) 1.66
The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol (1991) 1.65
Interactions between cell growth-regulating domains in the products of the adenovirus E1A oncogene. Mol Cell Biol (1988) 1.64
Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and myc oncoproteins. J Virol (1988) 1.63
The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol (1991) 1.59
Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J Virol (1991) 1.54
Mutational analysis of human papillomavirus type 16 E7 functions. J Virol (1990) 1.52
Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol Cell Biol (1991) 1.52
Transformation of a continuous rat embryo fibroblast cell line requires three separate domains of simian virus 40 large T antigen. J Virol (1992) 1.51
Identification of a region of simian virus 40 large T antigen required for cell transformation. J Virol (1990) 1.50
The zinc finger region of simian virus 40 large T antigen. J Virol (1989) 1.47
The ability of simian virus 40 large T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its ability to bind to p53. J Virol (1991) 1.46
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
trans-dominant mutants of E1A provide genetic evidence that the zinc finger of the trans-activating domain binds a transcription factor. Mol Cell Biol (1991) 1.39
Identification and analysis of a retinoblastoma binding motif in the replication protein of a plant DNA virus: requirement for efficient viral DNA replication. EMBO J (1995) 1.38
Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains. Mol Cell Biol (1992) 1.37
Role of the adenovirus E1B 19,000-dalton tumor antigen in regulating early gene expression. J Virol (1988) 1.36
Dissection of a carboxy-terminal region of the yeast regulatory protein RAP1 with effects on both transcriptional activation and silencing. Mol Cell Biol (1992) 1.35
The amino-terminal region of the adenovirus serotype 5 E1a protein performs two separate functions when expressed in primary baby rat kidney cells. Mol Cell Biol (1988) 1.34
The T/t common region of simian virus 40 large T antigen contains a distinct transformation-governing sequence. J Virol (1991) 1.32
DNA-binding properties of an adenovirus 289R E1A protein. EMBO J (1988) 1.31
DNA-binding properties of the E1A-associated 300-kilodalton protein. Mol Cell Biol (1992) 1.31
Adenovirus E1a ras cooperation activity is separate from its positive and negative transcription regulatory functions. Mol Cell Biol (1988) 1.30
Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J (1990) 1.27
The amino-terminal portion of CD1 of the adenovirus E1A proteins is required to induce susceptibility to tumor necrosis factor cytolysis in adenovirus-infected mouse cells. J Virol (1991) 1.25
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol (2001) 1.24
Ability of adenovirus 5 E1A proteins to suppress differentiation of BC3H1 myoblasts correlates with their binding to a 300 kDa cellular protein. Mol Biol Cell (1992) 1.24
Formation of the peroxisome lumen is abolished by loss of Pichia pastoris Pas7p, a zinc-binding integral membrane protein of the peroxisome. Mol Cell Biol (1995) 1.22
BS69, a novel adenovirus E1A-associated protein that inhibits E1A transactivation. EMBO J (1995) 1.21
The cellular transcription factor E2f requires viral E1A and E4 gene products for increased DNA-binding activity and functions to stimulate adenovirus E2A gene expression. J Virol (1989) 1.13
Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc Natl Acad Sci U S A (1991) 1.12
Induction of a cellular enzyme for energy metabolism by transforming domains of adenovirus E1a. Mol Cell Biol (1990) 1.11
Expression and interactions of human adenovirus oncoproteins. Biochem J (1991) 1.10
Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation. J Virol (1990) 1.08
Suppression of mutations in two Saccharomyces cerevisiae genes by the adenovirus E1A protein. Mol Cell Biol (1995) 1.07
Growth factor induction by the adenovirus type 5 E1A 12S protein is required for immortalization of primary epithelial cells. Mol Cell Biol (1988) 1.07
Immortalization of primary epithelial cells requires first- and second-exon functions of adenovirus type 5 12S. J Virol (1992) 1.06
An adenovirus E1A transcriptional repressor domain functions as an activator when tethered to a promoter. Nucleic Acids Res (1994) 1.05
Induction of sensitivity to the cytotoxic action of tumor necrosis factor alpha by adenovirus E1A is independent of transformation and transcriptional activation. J Virol (1990) 1.04
E1a transactivation of human HSP70 gene promoter substitution mutants is independent of the composition of upstream and TATA elements. Mol Cell Biol (1990) 1.03
Transrepression of RNA polymerase II promoters by the simian virus 40 small t antigen. J Virol (1994) 1.02
Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4. J Virol (1997) 1.02
The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB. Mol Cell Biol (1997) 1.02
Transcriptional control by adenovirus E1A conserved region 3 via p300/CBP. Nucleic Acids Res (2009) 1.01
Transcriptionally active immediate-early protein of pseudorabies virus binds to specific sites on class II gene promoters. J Virol (1989) 1.00
Charge configurations in viral proteins. Proc Natl Acad Sci U S A (1988) 0.99
Induction of c-fos mRNA and AP-1 DNA-binding activity by cAMP in cooperation with either the adenovirus 243- or the adenovirus 289-amino acid E1A protein. Proc Natl Acad Sci U S A (1991) 0.98
Rapid turnover of adenovirus E1A is determined through a co-translational mechanism that requires an aminoterminal domain. EMBO J (1988) 0.98
The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Res (1991) 0.97
The carboxy-terminal exon of the adenovirus E1A protein is required for E4F-dependent transcription activation. EMBO J (1992) 0.97
Identification of mouse adenovirus type 1 early region 1: DNA sequence and a conserved transactivating function. J Virol (1988) 0.97
Insulin gene enhancer activity is inhibited by adenovirus 5 E1a gene products. Mol Cell Biol (1989) 0.96
Simian virus 40 small t antigen trans activates the adenovirus E2A promoter by using mechanisms distinct from those used by adenovirus E1A. J Virol (1992) 0.95
Silencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant. Proc Natl Acad Sci U S A (1990) 0.95
The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K. Mol Cell Biol (1996) 0.94
Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol (1994) 0.93
The efficiency of adenovirus transformation of rodent cells is inversely related to the rate of viral E1A gene expression. J Virol (1990) 0.93
Use of recombinant retroviruses to study the regulation of integrated adenovirus early promoters. J Virol (1988) 0.92
Adenovirus type 12 E1A down regulates expression of a transgene under control of a major histocompatibility complex class I promoter: evidence for transcriptional control. J Virol (1989) 0.91
E1A-mediated activation of the adenovirus E4 promoter can occur independently of the cellular transcription factor E4F. Mol Cell Biol (1991) 0.90
Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene. Genes Cancer (2011) 0.87
Differential induction of cytolytic susceptibility by E1A, myc, and ras oncogenes in immortalized cells. J Virol (1989) 0.87
Genetic dissection of the transactivating domain of the E1a 289R protein of adenovirus type 2. J Virol (1989) 0.87
Cellular GCN5 is a novel regulator of human adenovirus E1A-conserved region 3 transactivation. J Virol (2012) 0.86
Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses (2015) 0.86
Upstream DNA sequences determine different autoregulatory responses of the adenovirus types 5 and 3 E1A promoters. J Virol (1989) 0.85
Repression of RNA polymerase III transcription by adenovirus E1A. J Virol (1993) 0.85
Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother (2014) 0.84
Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit. J Virol (2007) 0.84
Constructing chimeric type 12/type 5 adenovirus E1A genes and using them to identify an oncogenic determinant of adenovirus type 12. J Virol (1994) 0.83
Adenovirus L-E1A activates transcription through mediator complex-dependent recruitment of the super elongation complex. J Virol (2013) 0.83
Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res (1984) 86.56
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Dissecting the regulatory circuitry of a eukaryotic genome. Cell (1998) 23.62
Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro. Cell (1984) 12.30
Pre-mRNA splicing. Annu Rev Genet (1986) 9.86
Human beta-globin pre-mRNA synthesized in vitro is accurately spliced in Xenopus oocyte nuclei. Cell (1983) 9.77
Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (1994) 9.37
Excision of an intact intron as a novel lariat structure during pre-mRNA splicing in vitro. Cell (1984) 9.13
Transcription activation by the adenovirus E1a protein. Nature (1989) 9.08
Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev (1989) 7.47
Definition of a novel promoter for the major adenovirus-associated virus mRNA. Cell (1980) 7.42
Transcriptional activation of cloned human beta-globin genes by viral immediate-early gene products. Cell (1983) 7.22
Cloning and domain structure of the mammalian splicing factor U2AF. Nature (1992) 6.55
Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature (1994) 6.55
A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly. Cell (1988) 6.16
Mechanism of action of an acidic transcriptional activator in vitro. Cell (1991) 6.04
Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science (1995) 5.97
Facilitated binding of TATA-binding protein to nucleosomal DNA. Nature (1994) 5.95
Adenovirus DNA. I. Molecular weight and conformation. Proc Natl Acad Sci U S A (1967) 5.55
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med (1992) 5.42
Sequence-specific RNA binding by the HIV-1 Rev protein. Nature (1989) 5.36
Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell (1988) 5.26
Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc Natl Acad Sci U S A (1989) 5.11
Binding of general transcription factor TFIIB to an acidic activating region. Nature (1991) 4.71
A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell (1990) 4.67
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med (1990) 4.66
A mechanism for synergistic activation of a mammalian gene by GAL4 derivatives. Nature (1990) 4.57
An adenovirus E1a protein region required for transformation and transcriptional repression. Cell (1986) 4.56
An ordered pathway of snRNP binding during mammalian pre-mRNA splicing complex assembly. EMBO J (1987) 4.52
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell (1991) 4.43
cis and trans activation of globin gene transcription in transient assays. Proc Natl Acad Sci U S A (1983) 4.41
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Risk of lung cancer associated with residential radon exposure in south-west England: a case-control study. Br J Cancer (1998) 4.24
Transcription factor ATF interacts with the TATA factor to facilitate establishment of a preinitiation complex. Cell (1988) 4.15
An RNA processing activity that debranches RNA lariats. Science (1985) 4.14
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature (1993) 3.97
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst (1996) 3.95
A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. Gene Anal Tech (1989) 3.95
A cellular protein, activating transcription factor, activates transcription of multiple E1A-inducible adenovirus early promoters. Proc Natl Acad Sci U S A (1987) 3.91
Localization of pre-mRNA splicing in mammalian nuclei. Nature (1995) 3.88
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Functional recognition of the 3' splice site AG by the splicing factor U2AF35. Nature (1999) 3.72
A single subunit from avian myeloblastosis virus with both RNA-directed DNA polymerase and ribonuclease H activity. Proc Natl Acad Sci U S A (1973) 3.71
GAL4 derivatives function alone and synergistically with mammalian activators in vitro. Cell (1988) 3.67
Oncogenic viruses. Annu Rev Biochem (1970) 3.65
Vancomycin susceptibility and identification of motile enterococci. J Clin Microbiol (1991) 3.61
Specific and stable intron-factor interactions are established early during in vitro pre-mRNA splicing. Cell (1985) 3.59
Biochemical characterization of U2 snRNP auxiliary factor: an essential pre-mRNA splicing factor with a novel intranuclear distribution. EMBO J (1991) 3.54
Biochemical studies on adenovirus multiplication. 18. Resolution of early virus-specific RNA species in Ad 2 infected and transformed cells. Virology (1971) 3.54
Mammalian nuclei contain foci which are highly enriched in components of the pre-mRNA splicing machinery. EMBO J (1991) 3.49
Mechanism of carcinogenesis by RNA tumor viruses. I. An RNA-dependent DNA polymerase in murine sarcoma viruses. Proc Natl Acad Sci U S A (1970) 3.47
Interaction of a common cellular transcription factor, ATF, with regulatory elements in both E1a- and cyclic AMP-inducible promoters. Proc Natl Acad Sci U S A (1988) 3.46
Expressing the human genome. Nature (2001) 3.45
A cellular transcription factor E4F1 interacts with an E1a-inducible enhancer and mediates constitutive enhancer function in vitro. EMBO J (1987) 3.45
Cryptic branch point activation allows accurate in vitro splicing of human beta-globin intron mutants. Cell (1985) 3.25
SAGA is an essential in vivo target of the yeast acidic activator Gal4p. Genes Dev (2001) 3.23
Redundant roles for the TFIID and SAGA complexes in global transcription. Nature (2000) 3.21
Eukaryotic activators function during multiple steps of preinitiation complex assembly. Nature (1993) 3.16
Interaction of U2AF65 RS region with pre-mRNA branch point and promotion of base pairing with U2 snRNA [corrected]. Science (1996) 3.15
A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1. Genes Dev (1988) 3.13
The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev (1991) 3.08
HTLV-I Tax protein stimulation of DNA binding of bZIP proteins by enhancing dimerization. Science (1993) 3.05
Transcription activation in cells lacking TAFIIS. Nature (1996) 3.04
Occupational asthma in an electronics factory. Thorax (1979) 3.03
Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science (1993) 3.03
Evidence for interaction of different eukaryotic transcriptional activators with distinct cellular targets. Nature (1990) 3.03
Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science (2001) 3.03
Biochemical studies on adenovirus multiplication, XIX. Resolution of late viral RNA species in the nucleus and cytoplasm. Proc Natl Acad Sci U S A (1971) 3.02
Immunological identification of two adenovirus 2-induced early proteins possibly involved in cell transformation. Nature (1976) 3.01
A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature (1995) 2.98
How different eukaryotic transcriptional activators can cooperate promiscuously. Nature (1990) 2.91
Isolation of a human papillomavirus from a patient with epidermodysplasia verruciformis: presence of related viral DNA genomes in human urogenital tumors. Proc Natl Acad Sci U S A (1982) 2.90
Interaction between an acidic activator and transcription factor TFIIB is required for transcriptional activation. Nature (1993) 2.88
The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci (1996) 2.88
Immunoautoradiographic detection of proteins after electrophoretic transfer from gels to diazo-paper: analysis of adenovirus encoded proteins. Proc Natl Acad Sci U S A (1981) 2.88
Multiple functional domains of human transcription factor IIB: distinct interactions with two general transcription factors and RNA polymerase II. Genes Dev (1993) 2.87
The maximal sniff in the assessment of diaphragm function in man. Clin Sci (Lond) (1985) 2.83
Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA (1990) 2.82
Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. Proc Natl Acad Sci U S A (1992) 2.82
Biochemical studies on adenovirus multiplication. IX. Chemical and base composition analysis of 28 human adenoviruses. Proc Natl Acad Sci U S A (1965) 2.79
Enhancement of TBP binding by activators and general transcription factors. Nature (1999) 2.76
Yeast TAFIIS in a multisubunit complex required for activated transcription. Nature (1994) 2.74
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Controlling gene expression in living cells through small molecule-RNA interactions. Science (1998) 2.72
DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J Clin Microbiol (1995) 2.69
U2AF65 recruits a novel human DEAD box protein required for the U2 snRNP-branchpoint interaction. Genes Dev (1997) 2.67
Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci U S A (1991) 2.66
Role of the 3' splice site consensus sequence in mammalian pre-mRNA splicing. Nature (1985) 2.63
Splice site selection and ribonucleoprotein complex assembly during in vitro pre-mRNA splicing. Genes Dev (1988) 2.62
Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol (1993) 2.59
The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 2.55
Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum (1998) 2.51
Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature (1990) 2.47
Measurement of twitch transdiaphragmatic, esophageal, and endotracheal tube pressure with bilateral anterolateral magnetic phrenic nerve stimulation in patients in the intensive care unit. Crit Care Med (2001) 2.47